Navigation Links
Genomic Systems announces 'moratorium on studying and treating terminal cancer has ended'
Date:10/18/2010

PALO ALTO, CA (OCTOBER 15, 2010) Terminal metastatic cancer the presently untreatable cause of the great majority of all cancer deaths has now been effectively treated in three common fatal cancers in mice, according to announced Genomic Systems, citing research published online in the Proceedings of the National Academy of Sciences (PNAS).

Research conducted by Robert J. Debs, M.D., senior scientist at the California Pacific Medical Center Research Institute in collaboration with four other laboratories has shown that a monoclonal antibody targeting a protein called PECAM-1 is effective against this now invariably lethal stage of cancer in mice. This antibody also treats less advanced cancers, as well as the debilitating wasting syndrome that can develop as cancers progress.

Anti-PECAM-1-antibody produces its anti-cancer effects not by binding to tumor cells, but rather by binding to PECAM-1 on the surface of normal endothelial cells that line blood vessels. Because it acts through normal cells rather than directly on cancer cells, it is effective against a variety of different cancer types.

Laboratory testing has now shown anti-PECAM-1-antibody to be effective against colon cancer, breast cancer and melanoma. These are among the most frequently diagnosed fatal cancers in the United States, according to the National Cancer Institute.

"For the first time, preclinical studies provide hope for patients and their physicians that even the terminal stages of cancer do not invariably represent a hopeless situation. Our research has shown that some terminal cancers, as well as the debilitating wasting syndrome that can accompany them can now be treated in mice, said Dr. Debs. "Hopefully, these studies will encourage increased interest in studying terminal cancers, as well as stimulate others to develop additional new therapies that effectively target this most devastating stage of cancer."

The research also indicates that this antibody is well tolerated, even when administered at high doses to mice already debilitated by very advanced metastatic cancers. The antibody appears to work by selectively blocking PECAM-1's regulation of secreted proteins that promote advanced cancer's now lethal growth. Dr. Debs believes that specifically targeting these growth-promoting factors themselves may further improve the treatment of terminal cancer, and has the potential to significantly improve the lives of patients now suffering hopelessly from it.

"Preclinical studies focusing on terminal cancer are rare. Therefore, these patients have no therapies to either treat their cancer or give them hope. As a cancer specialist, all I could do for my patients with terminal cancers was to help make their remaining days as comfortable as possible," said Dr. Debs, who is trained as a medical oncologist and hematologist. "To be able to offer my patients with advanced cancers only palliative care and referral to hospice was not why I chose to become a cancer doctor. The profound, unmet medical and human needs of my patients in the terminal stages of cancer drove me into research."


'/>"/>

Contact: Mark Stuart
Reputation_Doctor@Live.com
425-898-0582
Reputation Doctor
Source:Eurekalert

Related medicine news :

1. Researchers chart genomic map spanning over 2 dozen cancers
2. SeqWright Advances Genomic Discovery With Isilon IQ
3. Lawrence Berkeley National Laboratory and OpenHelixTM Announce an Updated Free Tutorial Suite for VISTA: Tools for Comparative Genomics
4. Improvements needed in genomic test result discussions
5. Breast Cancer Patients Often Confused by Genomic Testing
6. Genentech uses Complete Genomics human genome sequencing service to compare tumor and normal genome in patient with non-small cell lung cancer; results published in Nature
7. Large-scale genomic analysis of prostate cancer unveiled
8. New genomic marker for tuberculosis may help identify patients who will develop the disease
9. St. Jude researcher receives grant to focus on cancer pharmacogenomics in children
10. Radiation pharmacogenomics identifies biomarkers that could personalize cancer treatment
11. La Jolla Institute to develop San Diegos first center for RNAi genomics research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... (PRWEB) , ... June 26, 2016 , ... Pixel Film ... Pro X. , "Film editors can give their videos a whole new perspective by ... Austin - CEO of Pixel Film Studios. , ProSlice Levels contains over 30 ...
(Date:6/26/2016)... ... , ... Brent Kasmer, a legally blind and certified personal trainer is helping to develop a ... fitness app plans to fix the two major problems leading the fitness industry today:, ... type program , They don’t eliminate all the reasons people quit their exercise ...
(Date:6/25/2016)... ... 25, 2016 , ... Experts from the American Institutes for ... Meeting June 26-28, 2016, at the Hynes Convention Center in Boston. , AIR ... care planning, healthcare costs and patient and family engagement. , AIR researchers will ...
(Date:6/25/2016)... ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library on June 21 due ... up a new, often overlooked aspect of head lice: the parasite’s ability to live away ... a common occurrence, but a necessary one in the event that lice have simply gotten ...
(Date:6/25/2016)... , ... June 25, 2016 , ... First Choice ... States, named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm ... Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... DUBLIN , June 24, 2016 ... addition of the "Structural Electronics 2015-2025: Applications, ... In-Mold Electronics, Smart ... Integrated Photovoltaics Structural electronics involves ... as load-bearing, protective structures, replacing dumb structures such ...
(Date:6/24/2016)... According to a new market ... Needles, Safety Pen Needles), Needle Length (4mm, 5mm, 6mm, ... of Purchase (Retail, Non-Retail) - Trends & Global Forecasts ... market for the forecast period of 2016 to 2021. ... by 2021 from USD 1.65 Billion in 2016, growing ...
(Date:6/23/2016)... , June 23, 2016 Research and ... Global Market - Forecast to 2022" report to their ... treatment method for the patients with kidney failure, it replaces ... fluid from the patient,s blood and thus the treatment helps ... and chloride in balance. Increasing number of ...
Breaking Medicine Technology: